Frazier Lifesciences (NASDAQ:FLAC) announced this morning that its shareholders have approved its business combination with biotech firm NewAmsterdam Pharma Holding during a special meeting today.
The SPAC disclosed that holders of approximately 32% of FLAC Class A ordinary shares exercised their right to redeem their shares for cash, significantly lower than the average redemption rate for completed deals this year at 83.99%.
Additionally, more than 90% of the votes cast at today’s meeting were cast in favor of the business combination. FLAC shareholders also voted to approve all other proposals.
FLAC now expects to close the deal on November 22, subject to the satisfaction or waiver of customary closing conditions. Upon closing, the ordinary shares and redeemable warrants of the combined company, NewAmsterdam Pharma Company, will be listed on The Nasdaq under the ticker symbols “NAMS” and “NAMSW” respectively, and are anticipated to begin trading on November 23.
The parties initially announced their $326 million combination on July 25, 2022. Netherlands-based NewAmsterdam is developing a range of drugs aimed at reducing patient cholesterol levels suffering from liver, heart and brain disorders.
ADVISORS
- Credit Suisse Securities (USA) LLC is acting as lead PIPE placement agent, financial advisor, and capital markets advisor to FLAC.
- Jefferies LLC is also acting as PIPE placement agents to FLAC and is acting as financial advisor and capital markets advisor to FLAC.
- SVB Securities LLC is also acting as PIPE placement agents to FLAC and is acting as financial advisor and capital markets advisor to the Company.
- William Blair & Company, L.L.C. is also acting as PIPE placement agents to FLAC and is acting as financial advisor and capital markets advisor to FLAC.
- Moelis & Co. is also acting as financial advisor to the Company.
- Covington & Burling LLP is acting as legal counsel to the Company.
- Goodwin Procter LLP is acting as legal counsel to FLAC.
- Kirkland & Ellis LLP is acting as legal counsel to the PIPE placement agents.
NMP Acquisition Corp. (NASDAQ:NMPAU) announced the pricing of its $100 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “NMPAU”, Tuesday, July 1, 2025. The new SPAC plans to combine with a target company that has a resilient business model with potential to scale up revenue. NMP’s management...
Cohen Circle Acquisition Corp. II (NASDAQ:CCIIU) announced the pricing of its $220 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “CCIIU”, Tuesday, July 1, 2025. The new SPAC plans to combine with a target company in the financial services technology (fintech) sector and fintech adjacent sectors that...
Indigo Acquisition Corp. (NASDAQ:INACU) announced the pricing of its $100 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “INACU”, Tuesday, July 1, 2025. The new SPAC plans to combine with an established, profitable company whose growth potential can benefit from its team’s expertise. Indigo’s management team is...
After a quiet June, July is set to be active throughout the month with nine de-SPACs and sponsors coming unlocked from their trading restrictions. This timing is most fortuitous for insurance investor Abacus Life (NASDAQ:ABL) and East Resources, which took it public in 2023, as it is the best performer of this group of companies...
Pyrophyte II (NYSE:PAII.U) has filed for a $175 million SPAC to dig for a natural resources target while the team’s first deal remains pending. The new SPAC is offering investors 1/2 warrants in each unit and it will have 24 months to complete a business combination without asking shareholders for an extension. It is the...